TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21801539
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of treatment benefit using absolute terms
Study: 21801539
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of treatment harm in relative terms
Study: 16942416
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (group T) - patients reported three times weekly via a secure Internet site.
Study: 15573017
Drug: Lavender therapy
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender therapy
Study: 1617576
Drug: Relaxing music
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxing music therapy
Study: 15573017
Drug: Lemon therapy
Normalized name: LEMON
DrugBank: Lemon (DB10538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon therapy
Study: 15573017
Drug: Preferred music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred music therapy
Study: 9431839
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg daily for 7 days
Study: 9431839
Drug: Zolmitriptan 10
Normalized name: zolmitriptan 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 10 mg single dose
Study: 8493214
Drug: High-dose cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cisplatin combined with ifosfamide and 5-fluorouracil
Study: 22749632
Drug: RT +
Normalized name: CVS Yogurt + Fiber Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT + CT (radiation therapy plus cisplatin, 100 mg/m² i.v. on days 1, 22, and 43)
Study: 22749632
Drug: RT (radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (radiation therapy, 60 Gy in 6 weeks)
Study: 18327362
Drug: Remifentanil (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.02 mg)
Study: 3731680
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 mg)
Study: 12181245
Drug: Marimastat 5
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 5 mg p.o. b.i.d. for 12 months
Study: 12181245
Drug: Marimastat 10
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 10 mg p.o. b.i.d. for 12 months
Study: 12181245
Drug: Marimastat 5
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 5 mg b.i.d. plus tamoxifen
Study: 12181245
Drug: Marimastat 10
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 10 mg b.i.d. plus tamoxifen
Study: 12181245
Drug: Marimastat 5
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 5 mg b.i.d.
Study: 12181245
Drug: Marimastat 10
Normalized name: Marimastat
DrugBank: Marimastat (DB00786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marimastat 10 mg b.i.d.
Study: 10194832
Drug: Rabipur vaccine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabipur vaccine, administered using the 2-1-1 schedule
Study: 10194832
Drug: Rabipur vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabipur vaccine
Study: 1941796
Drug: 0.4% terconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% terconazole cream
Study: 2381618
Drug: 0.8% terconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% terconazole cream
Study: 1941796
Drug: 2.0% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% miconazole nitrate cream
Study: 28834553
Drug: Exenatide (EXE)
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide (EXE) 10 μg BID
Study: 26032655
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 1000 mg BID
Study: 28834553
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) during second 12 weeks
Study: 17562253
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 40 mg/m(2) and vincristine 1.4 mg/m(2) (maximum, 2 mg) plus reduced‐dose dexamethasone 40 mg orally on days 1‐4 (DVd)
Study: 17562253
Drug: Conventional doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doxorubicin 9 mg/m(2) per day and vincristine 0.4 mg per day continuous intravenous infusion plus reduced‐dose dexamethasone (VAd)
Study: 14713761
Drug: Neoadjuvant or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant or adjuvant chemotherapy and radical cystectomy
Study: 19525519
Drug: sirolimus 2
Normalized name: sirolimus 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus 2 mg/day
Study: 12118900
Drug: sirolimus 5
Normalized name: SIROLIMUS 5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [FYARRO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus 5 mg/day
Study: 9717677
Drug: OspA vaccine
Normalized name: OspA protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: OspA vaccine (30-microgram dose)
Study: 2650588
Drug: 10 to
Normalized name: RE-10 Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 20 mg oral nifedipine
Study: 336013
Drug: 25% sodium
Normalized name: Dextrose 5% and 0.225% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% sodium fluorescein solution
Study: 336013
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium fluorescein solution
Study: 28934528
Drug: Lower altitude
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower altitude laboratory polysomnography (L-PSG)
Study: 22820718
Drug: Approved dose
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved dose of fospropofol (4.875 or 6.5 mg/kg depending on patient subgroup)
Study: 22820718
Drug: Weight-adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dose of fospropofol
Study: 22820718
Drug: Approved dose
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved dose of fospropofol
Study: 28394435
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OAC) therapy
Study: 10969261
Drug: Oat cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat cereal (24 grams per day, 1.2 ± 0.9 g/kg/d)
Study: 8771109
Drug: Autovac system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autovac system with calcium binding resin anticoagulant
Study: 8378945
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg twice daily
Study: 29952033
Drug: One-piece implant
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-piece implant system (STM)
Study: 29952033
Drug: Two-piece implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-piece implant system (BRA)
Study: 28916304
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of dilute mesenchymal stem cells (MSCs)
Study: 28916304
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of concentrated mesenchymal stem cells (MSCs)
Study: 18550961
Drug: C (Caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (Caffeine 300 mg)
Study: 18550961
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + E (Caffeine 300 mg + Ephedra 60 mg)
Study: 18550961
Drug: P (Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: P (Placebo 300 mg)
Study: 16210886
Drug: Once-daily administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily administration of fluticasone propionate (200 microg at night)
Study: 16210886
Drug: Twice-daily administration
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily administration of fluticasone propionate (100 microg in the morning and at night)
Study: 8336527
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (40 mmol of sodium daily)
Study: 8336527
Drug: High sodium
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sodium diet (120 mmol of sodium daily)
Study: 8336527
Drug: K-canrenoate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-canrenoate (200 mg/day increasing to 600 mg)
Study: 8336527
Drug: Furosemide (25-50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (25-50-100 mg every other day)
Study: 8336527
Drug: Washout period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Washout period of 7 days from outpatient diuretic regimen
Study: 29985433
Drug: Selective Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Triple Antithrombotic Therapy (TATT)
Study: 29985433
Drug: Ticagrelor-based Dual
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor-based Dual Antiplatelet Therapy (DAPT)
Study: 26653111
Drug: GH 1
Normalized name: Cough 100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1 mg/m(2)/d
Study: 26653111
Drug: GH 2
Normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 2 mg/m(2)/d
Study: 26653111
Drug: GH 1
Normalized name: Cough 100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1 mg/m(2)/d with GnRHa
Study: 26653111
Drug: GH 2
Normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 2 mg/m(2)/d with GnRHa
Study: 18388038
Drug: Policosanol 10
Normalized name: policosanol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 10 mg/d
Study: 11061069
Drug: Intention to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intention to seek treatment for UI
Study: 8889418
Drug: Aprotinin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 0.2 mg kg‐1 (group A)
Study: 8889418
Drug: Aprotinin 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 0.7 mg kg‐1 (group B)
Study: 8889418
Drug: Aprotinin 1
Normalized name: aprotinin 1.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 1 mg kg‐1 (group C)
Study: 8889418
Drug: Aprotinin 1.4
Normalized name: aprotinin 1.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 1.4 mg kg‐1 (group D)
Study: 31340849
Drug: Repetitive vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive vascular occlusion stimulus (RVOS) applied twice daily (once on day 1) for up to 10 days or until ICU discharge
Study: 8155434
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate cream
Study: 22807477
Drug: Individualised dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised dose of oral 17β-oestradiol (5-15 μg/kg per day for 2 years)
Study: 22807477
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of oral 17β-oestradiol (0.2 mg daily for the first year, 0.5 mg daily for the second year)
Study: 21225018
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray (200 μg in each nostril) once a day
Study: 21225018
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray (200 μg in each nostril) plus cetrizine (10 mg) orally once a day
Study: 21225018
Drug: Fluticasone nasal
Normalized name: fluticasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone nasal spray (200 μg in each nostril) plus montelukast (10 mg) orally once a day
Study: 17681971
Drug: Bilateral superficial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral superficial cervical plexus block with ropivacaine 0.487% plus clonidine 5 microg ml(‐1) (Group RC)
Study: 15754237
Drug: First treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: First treatment with lumbar paravertebral nerve root infiltration
Study: 526399
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Labetalol + Bethanidine)
Study: 30606273
Drug: IPS-WFM combination
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPS-WFM combination
Study: 30606273
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (equally intensive clinical treatment)
Study: 30448355
Drug: LUS-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUS-guided treatment strategy
Study: 30448355
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care treatment strategy
Study: 7128190
Drug: Benzydamine oral
Normalized name: benzydamine Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine oral rinse
Study: 16924985
Drug: Etch and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etch and rinse adhesive systems (SBMP, OS, SB1, G)
Study: 10908001
Drug: manualized, cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: manualized, cognitive‐behavioral outpatient treatment developed by the Matrix Center in Los Angeles
Study: 10908001
Drug: treatment approaches
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment approaches currently employed by the treatment sites
Study: 8700338
Drug: Mepartricin 150,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin 150,000 U (40 mg) once in the evening for 60 days
Study: 8700338
Drug: Mepartricin 50,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin 50,000 U (13 mg) t.d.s.
Study: 7058868
Drug: Baseline treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline treatments
Study: 27029546
Drug: Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Therapy (ST)
Study: 22295817
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture (treatment at Zhongwan (CV 12), Shangqu (KI 17) on healthy side, Huaroumen (ST 24) on affected side)
Study: 22295817
Drug: Acupuncture (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (treatment at Jianyu (LI 15), Jianliao (TE 14), Jianzhen (SI 9) on affected side)
Study: 7753957
Drug: 0.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 mg nicotine polacrilex
Study: 7753957
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nicotine polacrilex
Study: 7753957
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nicotine polacrilex
Study: 7753957
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg nicotine polacrilex
Study: 7753957
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg nicotine polacrilex
Study: 31568675
Drug: Testosterone (Sustanon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (Sustanon 250 mg)
Study: 27966406
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention preceding infertility treatment
Study: 25189222
Drug: PCT-guided antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided antimicrobial therapy
Study: 25189222
Drug: Standard antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimicrobial therapy (control group)
Study: 17978254
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of psychotropic medications prescribed
Study: 15805340
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg lidocaine
Study: 15805340
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg lidocaine
Study: 11940288
Drug: Thrombolysis combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis combined with anticoagulant therapy
Study: 11940288
Drug: Pure anticoagulant
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure anticoagulant therapy
Study: 11940288
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (combined)
Study: 9871816
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 or 40 mg/day)
Study: 9871816
Drug: Amitriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (50 or 100 mg/day)
Study: 7620114
Drug: Loxoprofen sodium
Normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen sodium 60 mg
Study: 8436153
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg
Study: 25851052
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg daily from 30-32 weeks of gestation until 1 month postpartum
Study: 30930022
Drug: TDF 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF 300 mg daily
Study: 23303244
Drug: Ringers acetate
Normalized name: Mimulus ringens whole extract
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ringers acetate (20 ml/kg)
Study: 23303244
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch 130/0.4 (10 ml/kg)
Study: 23303244
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ringers acetate and hydroxyethyl starch
Study: 20400652
Drug: Metoprolol immediate-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol immediate-release (IR) 50 mg with paroxetine
Study: 20400652
Drug: Metoprolol extended-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol extended-release (ER) 100 mg with paroxetine
Study: 20400652
Drug: Metoprolol immediate-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol immediate-release (IR) without paroxetine
Study: 20400652
Drug: Metoprolol extended-release
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol extended-release (ER) without paroxetine
Study: 7576170
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (n = 35)
Study: 28508838
Drug: Intra-hepatic arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-hepatic arterial weekly high-dose 5-fluorouracil (WHF)
Study: 28508838
Drug: Continuous venous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous venous infusion of 5-fluorouracil (CVI)
Study: 21370262
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg pramipexole
Study: 10828728
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ropinirole
Study: 16631247
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg x 3) with mental stress
Study: 16631247
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg x 3) with exercise
Study: 16631247
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg x 3) after postexercise meal
Study: 16631247
Drug: Repeated caffeine
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated caffeine doses throughout the test day
Study: 8385975
Drug: i.v. magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. magnesium sulphate 1 g h‐1 over 8 h
Study: 8385975
Drug: NaCl 18
Normalized name: K+ Chloride 50 MG / NaCl 180 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 18 mg h‐1 (control)
Study: 3825543
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g daily for 30 days (extended to 3 months for 3 patients)
Study: 3825543
Drug: Antacids 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids 350 mmol daily for 30 days (extended to 3 months for 4 patients)
Study: 10961748
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (NaP) solution
Study: 27476581
Drug: Camicinal (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal (50 mg)
Study: 20067974
Drug: Glimepiride up
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride up to 6 mg q.d.
Study: 18703934
Drug: Lithium (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (starting dose: 400 mg/day)
Study: 18703934
Drug: Valproate (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (starting dose: 20 mg/kg/day)
Study: 15307437
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment (40 mg/kg) - first treatment
Study: 15307437
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment (40 mg/kg) - second treatment
Study: 15307437
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment (40 mg/kg) - side effects
Study: 14612482
Drug: Parenteral opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral opioids
Study: 2862814
Drug: Phenoxybenzamine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoxybenzamine 20 mg